UCBJY:OTCMKTS
UCB
114,46 USD
arrow_downward
-0,87%(-1,01) 1 d.
16. 10., 16:00:00 GMT-4 · USD
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre UCBJY…
Otvoriť
114,95 USD
Vysoká
115,28 USD
Nízka
114,23 USD
Trh. kap.
39,39 mld.
Priem. obj.
53,31 tis.
Objem
70,57 tis.
Max. za 52 týž.
168,76 USD
Min. za 52 týž.
110,55 USD
Beta
0,57
Akcie v obehu
389,01 mil.
Počet zamestnancov
9 tis.
Otvoriť
114,95 USD
Vysoká
115,28 USD
Nízka
114,23 USD
Trh. kap.
39,39 mld.
Priem. obj.
53,31 tis.
Objem
70,57 tis.
Max. za 52 týž.
168,76 USD
Min. za 52 týž.
110,55 USD
Beta
0,57
Akcie v obehu
389,01 mil.
Počet zamestnancov
9 tis.
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
Seeking Alpha
·
pred 16 minútami
S&P 500 Earnings Yield Jumps Over 5%; Sold The EMXC
https://tech-insider.org/
·
pred 24 minútami
Nasdaq Futures Rebound 0.7% as Earnings Week Looms
marketscreener.com
·
pred 33 minútami
S&P 500 index slipped after the Stockholm exchange closed on Friday
Profil
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
Informácie o subjekte UCB
Generálny riaditeľJean-Christophe Tellier
Zamestnanci9 tis.
Dátum založenia18. 1. 1928
Hlavné sídlo-
Odvetvie-
Webucb.com